chrisvoncsefalvay/vaers-outcomes huggingface dataset:
My arm went dead and heart started racing before the needle came out of my arm. The guy said to sit there for 15 minutes. My right neck and back and right kidney felt inflamed a minute or so after shot. Face started getting tingly. Body started feeling heavy, went to sit in the chair from the table and couldn't really feel the floor. Sat down, my heart calmed down. Guy came back and asked how I was about 15 minutes later. I said my heart started racing and my arm went dead and neck and back got tight. I said my heartbeat seems to be better. He said I can go. Walking felt funny. I got to my car and just sat there for at least an hour. I may have been slightly disoriented but I don't really remember. I drove home, wasn't wise, felt weird driving. Kind of numb. I got home, thankfully. Sat down on the floor by the couch. Joints started to stiffen up. My hands felt funny. I took out my guitar to try and play and my hand wasn't really working. I persisted and about 15 minutes and it started coming back. Most of the side effects went away later that day I think, except for my neck and right side of my back and right kidney pain. It's two weeks today and my right kidney or right kidney area still feels tight
Non specific skin rash appeared on lower back then spread to arms over the course of the day. No other signs or symptoms were reported. Pt went to an urgent care facility where she recieved a prescription for a Medrol dose pack.
Shortly after receiving his second shot, he complained that he felt the same way as the first shot.  States that he felt the fatigue and lightheaded.  VS at 11:32 Am was 152/80-97% on room air- HR=70, Respirations=16.  Wife drove them to the clinic so encouraged them after about 45 minutes for him to go home and lay down.  Contact information on name card given to text me when they arrived at home and if any other sxs noted.
dx of peripheral neuropathy as state by pt's wife;has seen by 15 doctors so far for eval;
Initial report received from a healthcare professional on 23 October 2012. A 30-year-old pregnant female patient had received an intramuscular dose 1 of ADACEL vaccine (lot number U4421AA anatomical site of administration was not reported) on 23 October. The patient's last menstrual period date was 12 April 2012. The estimated date of delivery was 27 January 2013. At the time of the report, the patient had not experienced any adverse events. The patient's health during pregnancy, risk factors was not reported. Concomitant medications and past medical history was not reported. Documents held by sender: None. Follow-up information was received from a healthcare professional on 02 August 2013. Based on the new information, this case has been upgraded to serious. The patient also received RhoGam (lot number, route and site not reported). The patient experienced thrombocytopenia (date not reported). The baby was large for gestational age (LGA). The patient had an ASCUS pap with negative colposcopy (date not reported). End of pregnancy date was 14 January 2013. The infant and birth outcome were normal. This was the patient's first pregnancy. Patient's outcome was not reported.
Redness & warmth to injection sites on (L) arm. No fever, no hives.
Presented to ED with fever, not feeling well and swollen lymph nodes in left arm. Received MMR and Tdap on 8/8/2016 in left arm.
Tendernessand pain  at injection site; Redness about the size of a golf ball around injection site; area was warm to the touch; This case was reported by a consumer via call center representative and described the occurrence of injection site tenderness in a 69-year-old male patient who received Herpes zoster (Shingrix) for prophylaxis.   The patient's past medical history included shingles (outbreak of Shingles in 2005) and shingles (outbreak of Shingles in April 2021). Previously administered products included Shingrix (received 1st dose in December 2021).   On 25th June 2022, the patient received the 2nd dose of Shingrix. In June 2022, 24 hrs after receiving Shingrix, the patient experienced injection site erythema and injection site warmth. On 25th June 2022, the patient experienced injection site tenderness. On an unknown date, the outcome of the injection site tenderness, injection site erythema and injection site warmth were not recovered/not resolved.   It was unknown if the reporter considered the injection site tenderness, injection site erythema and injection site warmth to be related to Shingrix.     Additional Information: GSK Receipt Date: 28-Jun-2022 Reporter's Comments: The patient self-reported this case. The patient reported developing large area of redness about the size of a golf ball around the injection site approximately 24 hours after receiving second dose of Shingrix. The patient also experienced tenderness and pain at the injection site immediately after receiving dose. The patient noticed the area was warm to the touch approximately 24 hours after receiving dose. The reporter wondered if previously experiencing two outbreaks of Shingles (in 2005 and April of 2021) had anything to do with his reaction to the second dose of Shingrix, as he typically had no reaction to vaccines. The reporter consented to follow up.
Sore neck; Sore jaw; This is a spontaneous report from a non-contactable consumer, the patient. A 50-year-old female patient received the first dose of BNT162b2 (PFIZER-BIONTECH COVID-19 mRNA VACCINE; Lot Number: ER8733) via an unspecified route of administration in the arm left on 07Apr2021 at 09:00 (at the age of 50-year-old) as a single dose for COVID-19 immunisation. Medical history included an allergy to latex powder. The patient did not receive any other medications within two weeks of vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the vaccination. On 07Apr2021, on the same day of vaccination, the patient experienced a sore neck and a sore jaw. The events did not result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Therapeutic measures were not taken as a result of the events. The clinical outcome of the events sore neck and sore jaw were recovered on 07Apr2021.   No follow-up attempts are possible. No further information is expected.
This spontaneous report was received from a consumer refers to his son of unknown age. The patient's pertinent medical history and concurrent conditions were not provided. On an unknown date, the patient was vaccinated with the fourth dose of GARDASIL 0.5 ml, intramuscular (lot number and expiration date were not provided). Concomitant therapy information was not provided. On an unknown date, there was an extra dose administered as the patient received a fourth dose of GARDASIL. No adverse event was reported. It was unknown if the patient sought medical attention. At the time of the report, the patient's status was unknown. Additional information is not expected. No contact details were provided.
Left deltoid warm, hard, swollen on 03/01/2005 at night after DTAP given in left deltoid. Red area 11.5 cm x 10cm. Patient has full range of motion and complains of site itching but not painful. Fever last night but temperature at 05:15 was 98.3 degrees Fahrenheit. No treatment necessary per MD. She recovered when left office.
Missed to receive the 2nd dose of Moderna vaccine; cold; fever; Tested positive for Covid infection by mid April after receiving the 1st dose of vaccine; This spontaneous case was reported by a consumer and describes the occurrence of INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Missed to receive the 2nd dose of Moderna vaccine), NASOPHARYNGITIS (cold), PYREXIA (fever) and COVID-19 (Tested positive for Covid infection by mid April after receiving the 1st dose of vaccine) in a 51-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 16-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, the patient experienced INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Missed to receive the 2nd dose of Moderna vaccine), NASOPHARYNGITIS (cold), PYREXIA (fever) and COVID-19 (Tested positive for Covid infection by mid April after receiving the 1st dose of vaccine). At the time of the report, INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION (Missed to receive the 2nd dose of Moderna vaccine) had resolved and NASOPHARYNGITIS (cold), PYREXIA (fever) and COVID-19 (Tested positive for Covid infection by mid April after receiving the 1st dose of vaccine) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): In April 2021, SARS-CoV-2 test: positive (Positive) positive.     The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No Relevant concomitant medications was reported.  Treatment information was not provided.
Increase blood pressure  ,  fatigue, with second shot very dizzy. Doctor put off for 2 days till blood pressure came down
fever of 104.5 for 2 1/2 days beginning 2MAR95 @ 10AM; treated w/Tempra; 2MAR95 9PM while sleeping had a startling jerk 3 times w/in 30 mins; 2MAR95 large red bump & swelling on both legs @ inj site for 2 days;
Having lupus effect extra side effects; This spontaneous case was reported by a consumer and describes the occurrence of IMMUNISATION REACTION (Having lupus effect extra side effects) in a  patient of an unknown age and gender who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) for COVID-19 prophylaxis.     No Medical History information was reported.    On an unknown date, the patient received dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On an unknown date, the patient experienced IMMUNISATION REACTION (Having lupus effect extra side effects). At the time of the report, IMMUNISATION REACTION (Having lupus effect extra side effects) outcome was unknown.        For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter did not provide any causality assessments.   No concomitant product was reported. No treatment information was reported.   Most recent FOLLOW-UP information incorporated above includes: On 27-Feb-2023: Follow-up received included no new information.
COVID 19 Treatment; COVID 19 Treatment; This is a spontaneous report received from contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 65-year-old male patient received BNT162b2 (BNT162B2), on 25Mar2021 at 12:45 as dose 1, single (Lot number: ER8733), in left arm, on 15Apr2021 at 14:00 as dose 2, single (Lot number: EW0169), in left arm and on 31Jan2022 at 12:30 as dose 3 (booster), single (Lot number: FM0698) at the age of 65 years, in left arm for covid-19 immunisation. The patient had no relevant medical history. There were no concomitant medications. The following information was reported: DRUG INEFFECTIVE (medically significant), COVID-19 (medically significant), outcome "recovered" (13Jun2022) and all described as "COVID 19 Treatment". The patient underwent the following laboratory tests and procedures: SARS-CoV-2 test: (unspecified date) Positive, notes: I tested positive once again using a home antigen test; (unspecified date) Positive, notes: I tested positive once again; (unspecified date) Negative, notes: I tested negative using home antigen test; (08Jun2022) Negative, notes: home antigen test is now negative. Therapeutic measures were taken as a result of vaccination failure, covid-19. Clinical information: COVID-19 rebound--after I completed the Paxlovid treatment all symptoms of Covid-19 were gone and I tested negative using home antigen test. 6 days after initial recovery there was a recurrence of Covid-19 symptoms and I tested positive once again using a home antigen test. Symptoms were fairly mild--low grade fever of 99.5°F, sore throat & cough, low energy. Symptoms cleared up within 5 days & home antigen test is now negative. No follow-up attempts are needed. No further information is expected.
Client fully vaccinated with Pfizer vaccine for Covid on April 1 and April 22, 2021.  On July 20, client developed Covid symptoms (fatigue, fever x 2 days, loss of taste and smell).  Tested positive for Covid with rapid test on 7/24.  Reported as a breakthrough case of Covid in a previously fully vaccinated person.
SHORTNESS OF BREATH; PAIN IN BILATERAL LEGS; PAIN IN BILATERAL HIPS; This spontaneous report received from a patient concerned a 54 year old female. The patient's weight was 200 pounds, and height was 158 centimeters. The patient's concurrent conditions included hypothyroidism, high blood pressure, diabetes type 2(non-insulin dependent), hyperlipidemia, alcohol use, and non smoker, and other pre-existing medical conditions included the patient had no known allergies and did not had any history of drug abuse or illicit drug use. The patient received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin not reported, batch number: 0422A21A and expiry: UNKNOWN) dose was not reported, administered on 03-APR-2021 for prophylactic vaccination. No concomitant medications were reported.  On 09-APR-2021, the subject experienced shortness of breath. On 09-APR-2021, the subject experienced pain in bilateral legs. On 09-APR-2021, the subject experienced pain in bilateral hips. The action taken with covid-19 vaccine ad26.cov2.s was not applicable. The patient recovered from shortness of breath, pain in bilateral legs, and pain in bilateral hips on 11-APR-2021. This report was non-serious.; Sender's Comments: V0: Medical Assessment comment not required per standard procedure as the case is assessed as non-serious.
Patient history of asthma, COPD.  Patient brought to the ED by EMS  on 11/29 for lethargy and confusion. The day prior, patient's living facility staff collected a dark brown urine sample that was sent for evaluation. EMS reports patient had a temperature of 99.5 F, and noted patient was tachycardic and breathing rapidly.  COVID PCR test completed in the ED also resulted positive. Patient admitted 11/29 - 12/9 for COVID-19 infection, sepsis, suspected UTI, anemia.
Severe Joint Pain, Severe Inflammation, thrush, caused joint sublexion in all joints to the point of dislocation. Change in bowel and bladder. Undergoing testing as it seems to be getting worse. Developed cysts. Abdominal pain in Kidney and liver area--unknown. Severe bone ache especially at night. severe fatigue in joints to this date(19Sep22)
Sore arm; This spontaneous case was reported by a consumer and describes the occurrence of VACCINATION SITE PAIN (Sore arm) in a  patient of an unknown age and gender who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     No Medical History information was reported.    On 07-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 07-Jan-2021, the patient experienced VACCINATION SITE PAIN (Sore arm). At the time of the report, VACCINATION SITE PAIN (Sore arm) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       Concomitant medication details were not reported by the reporter. Treatment details was not reported by the reporter.
experienced on her left arm from the injection site to elbow a black and blue swelling; soreness at the injection; Sensitivity at injection site; on the entire right side of the body had a tingling; on the entire right side of the body had a burning sensation/ it was burning; insensitive; right side from the scalp all the way down to her legs had a weird sensation; soreness, sensitivity, and swelling at the injection site that prevented her from sleeping/ Trouble sleeping; experienced on her left arm from the injection site to elbow a black and blue swelling; This case was reported by a pharmacist and described the occurrence of extensive swelling of vaccinated limb in a 67-year-old female patient who received Herpes zoster (Shingrix) (batch number DP95H, expiry date 15th April 2022) for prophylaxis.   Previously administered products included Pneumonia vaccine (received on an unknown date), Flu vaccine (received on an unknown date) and TDap vaccine (received on an unknown date).   On 16th June 2020, the patient received the 1st dose of Shingrix (intramuscular) .5 ml. On 16th June 2020, less than a day after receiving Shingrix, the patient experienced extensive swelling of vaccinated limb, injection site pain, injection site hypersensitivity, tingling, burning sensation skin, numbness, weird feeling, difficulty sleeping and skin discoloration. On 19th June 2020, the outcome of the extensive swelling of vaccinated limb, injection site pain, injection site hypersensitivity, tingling, burning sensation skin, numbness, weird feeling, difficulty sleeping and skin discoloration were recovered/resolved.   It was unknown if the reporter considered the extensive swelling of vaccinated limb, injection site pain, injection site hypersensitivity, tingling, burning sensation skin, numbness, weird feeling, difficulty sleeping and skin discoloration to be related to Shingrix.  Additional details were provided as follows:  The patient had received other vaccines (pneumonia, TDap, and flu) without any problems.  The 1st dose was given in the patient's left arm.  The right side from the scalp all the way down to her legs had a weird sensation. It was burning and tingling. The patient had soreness, sensitivity and swelling at the injection site that prevented her from sleeping, as well as a black and blue discoloration along with swelling of the skin that went from the injection site to the elbow.  These reactions lasted about 3 days, with the second day being the worst.  The reporter consented to follow up. The reporter provided the contact information and did not have an email to provide.; Sender's Comments:  US- GLAXOSMITHKLINE-US2020251615:same reporter
Due to a dog bite I was given a tetanus shot and the next day my arm started getting red and it was bright red from shoulder to elbow in a couple days. After that went away in a week I had pain in my arm and had about to have therapy on it and i still do not have full range of motion.
Nausea 8pm 4/15, vomiting4/16 1am, diarrhea, fever 4/17 2am, 4/17-19 fatigue, , muscle pain.
Information has been received from a school nurse concerning a pt who was vaccinated "IM" with a dose of varicella virus vaccine live. It was reported that the child got shingles described as a small ring of papules on the back with a trail to the left or right. Unspecified medical attention was sought. No treatment was required. No product quality complaint was involved. Additional information has been requested.
About 6 x 6cm raised, red, tender warm lesion at site of injection. Afebrile. Tx'd with Keflex for presumptive cellulitis.
Very sore arm, headache, chills and 100.4 F temperature.  Currently, resting in bed.
4 days after the vaccine patient started to have tinnitus, then a week after that patient started to have stinging, numbness, burning sensation in the extremities, that increased with daily activities.
Went into pharmacy and pharmacist never asked about current meds. I had no literature presented to me before shot. I asked her questions and then she mentioned that TYLENOL has a drug interaction with vaccine. I told her I took LORTAB which has TYLENOL but she did not know what to say as to whether there will be an interaction.  I also asked her whether to take Flu and Pneumonia vaccine together or separately; she did not provide a good response. I decided to take the 2 of them. I had a prescription to receive the over 65 years pneumonia however I'm not sure whether I received the correct one since when I got home I reviewed the paperwork and it specified it was for the pneumonia vaccine for 65 and under. I called another pharmacy to ask about the interaction between LORTAB/TYLENOL and the vaccines but the staff specified they did not know. At night the pain began I and tried to take deep breaths to help control the pain but it did not work. Did not have problems with the Flu but had problems with the pneumonia vaccine. Patient usually goes to the bathroom often at one but at one point had sharp pain in the left part of the neck but ignored it and went to sleep. 90 minutes later got up to the bathroom and had shooting pain in the whole back all the way to the buttocks. Patient put blanket on and lay flat which helped back a little. I had to take LORTAB by midnight and some more by 6am. Right now still has pain but not as severe. She also had a soft stomach with these issues. At this point not sure when can start taking LORTAB again but is following up with doctor.
pt cried 3 1/2 hrs p/vax; rash on chest;slept 20hr p/shots, not crying now;not stiff neck;no difficulty breathing;t99.9 ax;
not yet received the second dose; This case was reported by a pharmacist via call center representative and described the occurrence of incomplete course of vaccination in a 35-year-old female patient who received HBV (Engerix B) for prophylaxis.   Previously administered products included Engerix b (1st dose received on 22nd December 2020, batch number bg92z, expiry date 4th July 2022).   On an unknown date, the patient received the 2nd dose of Engerix B. On an unknown date, unknown after receiving Engerix B, the patient experienced incomplete course of vaccination. On an unknown date, the outcome of the incomplete course of vaccination was unknown.  Additional details were provided as follows: The age at vaccination was not applicable for this report. The patient had received the first dose of the Engeri B and had not yet received the second dose of the schedule, which led to incomplete course of vaccination. No further events were reported. The reporter agreed to contacted for follow-up. Did not consent to follow-up.
soreness in her mouth /  mouth is still tender; blisters/lesions/ulcers in her mouth on the tongue and along the gums; ulcers in her mouth on the tongue and along the gums; lesions in her mouth on the tongue and along the gums; body aches; chills; fever; This case was reported by a consumer via call center representative and described the occurrence of oral pain in a female patient who received Herpes zoster (Shingrix) for prophylaxis.   Previously administered products included Shingrix with an associated reaction of pain in extremity (received 1st dose 3 months ago,refer case US2020AMR228248).   On 13th November 2020, the patient received the 2nd dose of Shingrix. On 14th November 2020, 1 days after receiving Shingrix, the patient experienced general body pain, chills and fever. On 16th November 2020, the patient experienced oral pain, blistering of mouth, mouth ulcer and oral lesion. On an unknown date, the outcome of the oral pain was not recovered/not resolved and the outcome of the general body pain, chills, fever and blistering of mouth were recovered/resolved and the outcome of the mouth ulcer and oral lesion were unknown.   It was unknown if the reporter considered the oral pain, general body pain, chills, fever, blistering of mouth, mouth ulcer and oral lesion to be related to Shingrix.  Additional details were provided as follows: The age at vaccination was not reported. The patient received Shingrix around 6 pm and experienced fever, chills, and body aches which lessened and had gone away.  The patient noticed soreness in her mouth and says that there are small blisters, lesions and ulcers in her mouth on the tongue and along the gums.  The patient was wondering if this could be a reaction to Shingrix.  This had not yet resolved and mouth was still tender and she only eat soft food. The caller did not want to provide the contact information for the pharmacy and did not want to answer any further questions.  The caller did not want to provide her personal address and provided limited information.; Sender's Comments:  US-GLAXOSMITHKLINE-US2020AMR228248:same patient